Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients

https://www.news-medical.net/news/20260529/Pembrolizumab-combination-therapy-improves-survival-in-recurrent-endometrial-cancer-patients.aspx Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone. Notably, this benefit was observed in both the mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) populations. An analysis of the study data, with prolonged follow-up, demonstrated that there was a sustained numerical benefit in overall survival for patients who received pembrolizumab with chemotherapy even when a large proportion of the initial placebo treated patients received post-protocol immunotherapy. These results were presented during the Gynecologic Oncology Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.